ERT Launches Multi-Language Platform
Native language capabilities significantly improve site performance and clinical data quality
Philadelphia, PA – ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced a significant enhancement to MasterScope, the company’s flagship platform for centralized respiratory clinical trials, making it the industry’s first and only multi-language solution.
With multi-language capabilities, MasterScope enables sites to manage respiratory trials in their native language, which saves time, reduces the risk of protocol compliance errors, and improves overall data quality. Sponsors can now confidently expand the scope of countries in their trials, removing language as a barrier to site performance.
“Respiratory trials are highly complex, requiring investigative site personnel to guide patients through precise maneuvers in order to collect accurate data that supports drug efficacy and safety claims,” said Achim Schülke, Executive Vice President, Respiratory Solutions at ERT. “Assuming all site personnel and patients can comprehend English well enough to accurately follow these workflows is impractical. With these enhancements to MasterScope, sponsors running global cardiopulmonary trials can now add native language capabilities to reduce another level of risk while increasing site compliance.”
ERT’s MasterScope supports any clinical trial that requires spirometry measurements, including those that also collect Fractional exhaled Nitric Oxide (FeNO), electrocardiogram (ECG), home spirometry, and electronic Clinical Outcome Assessment (eCOA) data.
For more information on ERT’s suite of Respiratory Solutions, visit http://www.ert.com/respiratory.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information, see www.ert.com. Join ERT on LinkedIn, Twitter, YouTube and Facebook.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
